Comparative Pharmacology
Head-to-head clinical analysis: GANTANOL DS versus MICROSUL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GANTANOL DS versus MICROSUL.
GANTANOL-DS vs MICROSUL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydrofolate synthesis by competing with para-aminobenzoic acid, thereby blocking folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, converting dihydrofolate to tetrahydrofolate. This sequential blockade produces bactericidal activity.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
2 g (DS strength: 2 g sulfamethoxazole/400 mg trimethoprim) orally every 12 hours for 14-21 days for Pneumocystis jirovecii pneumonia.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
None Documented
None Documented
10-12 hours (sulfamethoxazole component); prolonged in renal impairment (up to 30 hours with CrCl <15 mL/min).
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
Primarily renal (70-100%) as unchanged drug and inactive metabolites (sulfamethoxazole N4-acetyl and glucuronide conjugates); <5% biliary/fecal.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic